Mutations affecting synaptic levels of neurexin-1β in autism and mental retardation

Neurobiology of Disease

Volumn 47, Issue 1, 2012, Pages 135-143

  Camacho Garcia, Rafael J ^a   Planelles, Ma Inmaculada ^b   Margalef, Mar ^b   Pecero, Maria L ^a,d   Martínez Leal, Rafael ^b   Aguilera, Francisco ^b   Vilella, Elisabet ^c   Martinez Mir, Amalia ^a   Scholl, Francisco G ^a,d  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^c Reus   (Spain)

^d UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Autism; Mental retardation; Mutation; Neurexin; Synapse

Indexed keywords

NEUREXIN; NEUREXIN 1 BETA; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; AUTISM; CODON; CONTROLLED STUDY; DNA DETERMINATION; EXON; EXTRACELLULAR SPACE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; NEUREXIN 1 BETA GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROCESSING; SYNAPSE; TRANSLATION INITIATION;

ADULT; AUTISTIC DISORDER; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTELLECTUAL DISABILITY; MALE; MENTAL DISORDERS; MIDDLE AGED; MUTATION; NERVE TISSUE PROTEINS; SYNAPSES;

EID: 84861230108     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.03.031     Document Type: Article

References (46)

1. Abrahams B.S., Geschwind D.H. Advances in autism genetics: on the threshold of a new neurobiology. Nat. Rev. Genet. 2008, 9:341-355.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington DC. 4th ed.
3. Baird G., et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 2006, 368:210-215.
4. Berkel S., et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat. Genet. 2010, 42:489-491.
5. Bot N., et al. Processing of the synaptic cell adhesion molecule neurexin-3beta by Alzheimer disease alpha- and gamma-secretases. J. Biol. Chem. 2011, 286:2762-2773.
6. Boucard A.A., et al. A splice code for trans-synaptic cell adhesion mediated by binding of neuroligin 1 to alpha- and beta-neurexins. Neuron 2005, 48:229-236.
7. Bourgeron T. A synaptic trek to autism. Curr. Opin. Neurobiol. 2009, 19:231-234.
8. Bucan M., et al. Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. PLoS Genet. 2009, 5:e1000536.
9. Chih B., et al. Disorder-associated mutations lead to functional inactivation of neuroligins. Hum. Mol. Genet. 2004, 13:1471-1477.
10. Chih B., et al. Alternative splicing controls selective trans-synaptic interactions of the neuroligin-neurexin complex. Neuron 2006, 51:171-178.
11. Ching M.S., et al. Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum of developmental disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:937-947.
12. Dean C., et al. Neurexin mediates the assembly of presynaptic terminals. Nat. Neurosci. 2003, 6:708-716.
13. Durand C.M., et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat. Genet. 2007, 39:25-27.
14. Feng J., et al. High frequency of neurexin 1beta signal peptide structural variants in patients with autism. Neurosci. Lett. 2006, 409:10-13.
15. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J. Autism Dev. Disord. 2003, 33:365-382.
16. Gauthier J., et al. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum. Genet. 2011, 130:563-573.
17. Guilmatre A., et al. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Arch. Gen. Psychiatry 2009, 66:947-956.
18. Jamain S., et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat. Genet. 2003, 34:27-29.
19. Kim H.G., et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am. J. Hum. Genet. 2008, 82:199-207.
20. Kirov G., et al. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum. Mol. Genet. 2008, 17:458-465.
21. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 1986, 44:283-292.
22. Kozak M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 1987, 15:8125-8148.
23. Kozak M. Emerging links between initiation of translation and human diseases. Mamm. Genome 2002, 13:401-410.
24. Laumonnier F., et al. X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am. J. Hum. Genet. 2004, 74:552-557.
25. McClellan J., King M.C. Genomic analysis of mental illness: a changing landscape. JAMA 2010, 303:2523-2524.
26. Missler M., Sudhof T.C. Neurexins: three genes and 1001 products. Trends Genet. 1998, 14:20-26.
27. Mitchell K.J. The genetics of neurodevelopmental disease. Curr. Opin. Neurobiol. 2011, 21:197-203.
28. Moessner R., et al. Contribution of SHANK3 mutations to autism spectrum disorder. Am. J. Hum. Genet. 2007, 81:1289-1297.
29. O'Roak B.J., et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat. Genet. 2011, 43:585-589.
30. Persico A.M., Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci. 2006, 29:349-358.
31. Pesole G., et al. Analysis of oligonucleotide AUG start codon context in eukariotic mRNAs. Gene 2000, 261:85-91.
32. Pinto D., et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010, 466:368-372.
33. Rujescu D., et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum. Mol. Genet. 2009, 18:988-996.
34. Saura C.A., et al. Presenilin/gamma-secretase regulates neurexin processing at synapses. PLoS One 2011, 6:e19430.
35. State M.W. The genetics of child psychiatric disorders: focus on autism and Tourette syndrome. Neuron 2010, 68:254-269.
36. Sudhof T.C. Neuroligins and neurexins link synaptic function to cognitive disease. Nature 2008, 455:903-911.
37. Sundaram S.K., et al. Tourette syndrome is associated with recurrent exonic copy number variants. Neurology 2010, 74:1583-1590.
38. Suzuki Y., et al. Statistical analysis of the 5' untranslated region of human mRNA using "Oligo-Capped" cDNA libraries. Genomics 2000, 64:286-297.
39. Szatmari P., et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat. Genet. 2007, 39:319-328.
40. Toro R., et al. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet. 2010, 26:363-372.
41. Tucker P., et al. The eyeless mouse mutation (ey1) removes an alternative start codon from the Rx/rax homeobox gene. Genesis 2001, 31:43-53.
42. Ushkaryov Y.A., et al. Conserved domain structure of beta-neurexins. Unusual cleaved signal sequences in receptor-like neuronal cell-surface proteins. J. Biol. Chem. 1994, 269:11987-11992.
43. Yan J., et al. Neurexin 1alpha structural variants associated with autism. Neurosci. Lett. 2008, 438:368-370.
44. Zahir F.R., et al. A patient with vertebral, cognitive and behavioural abnormalities and a de novo deletion of NRXN1alpha. J. Med. Genet. 2008, 45:239-243.
45. Zhang C., et al. A neuroligin-4 missense mutation associated with autism impairs neuroligin-4 folding and endoplasmic reticulum export. J. Neurosci. 2009, 29:10843-10854.
46. Zweier C., et al. CNTNAP2 and NRXN1 are mutated in autosomal-recessive Pitt-Hopkins-like mental retardation and determine the level of a common synaptic protein in Drosophila. Am. J. Hum. Genet. 2009, 85:655-666.